摘要
目的分析贝伐珠单抗(Bev)联合不同化疗方案治疗转移性结直肠癌(mCRC)的疗效及安全性。方法回顾性分析2016年3月—2017年6月我院48例行Bev联合标准双周方案化疗的mCRC患者的临床资料,按照治疗方案不同分为A组和B组。A组22例,B组26例。A组采用Bev+FOLFIRI方案,B组Bev+FOLFOX方案。治疗结束后评估近期疗效,比较2组患者血清肿瘤标志物[癌胚抗原(CEA)、糖类抗原125(CA125)、糖类抗原199(CA199)]水平,观察不良反应及预后情况。结果2组近期疗效比较差异无统计学意义(P>0.05)。2组治疗后血清CEA、CA125、CA199水平均较治疗前降低(P<0.05),上述指标组间比较差异无统计学意义(P>0.05)。2组无进展生存期和不良反应发生情况比较差异无统计学意义(P>0.05)。结论Bev联合FOLFIRI或FOLFOX方案治疗mCRC疗效相当,不良反应均主要为轻中度,患者可耐受,故均可作为治疗mCRC的理想方案。
Objective To analyze efficacy and safety of Bevacizumab(Bev)combined with different chemotherapy regimens in treatment of patients with metastatic colorectal cancer(mCRC).Methods Clinical data of 48 mCRC patients undergoing Bev combined with standard biweekly chemotherapy regimen during March 2016 and June 2017 was retrospectively analyzed,and the patients were divided into group A(n=22)and group B(n=26)according to different therapeutic regimens.Group A was treated with Bev+FOLFIRI regimen,while group B was treated with Bev+FOLFOX regimen.After treatment,short-term efficacy was evaluated,and levels of serum tumor markers[carcino-embryonic antigen(CEA),carbohydrate antigen 125(CA125)and carbohydrate antigen 199(CA199)]were compared,and conditions of adverse reaction and prognosis were observed in two groups.Results There was no significant difference in short-term efficacy between two groups(P>0.05).After treatment,levels of serum CEA,CA125 and CA199 were significantly lower than those before treatment in two groups(P<0.05),but there were no significant differences in the above indexes between groups(P>0.05).There were no significant differences in progression-free survival time and incidence rate of adverse reactions between two groups(P>0.05).Conclusion Bev combined with FOLFIRI or FOLFOX regimens has similar efficacy in treatment of patients with metastatic colorectal cancer,Adverse reactions are mainly mild to moderate and can be tolerated by patients,and therefore both of the regimens may be used as ideal regimens in treatment of metastatic colorectal cancer.
作者
韩建雄
骆成俊
杨波
尹川
罗莉
刘彦
HAN Jian-xiong;LUO Cheng-jun;YANG Bo;YIN Chuan;LUO Li;LIU Yan(Department of Gastroenterology,the Fifth People's Hospital of Chengdu,Chengdu 610000,China;Department of Obstetrics and Gynecology,the Fifth People's Hospital of Chengdu,Chengdu 610000,China)
出处
《解放军医药杂志》
CAS
2019年第10期27-30,共4页
Medical & Pharmaceutical Journal of Chinese People’s Liberation Army
基金
2017年四川省卫生和计划生育委员会科研课题(17ZD008)
2016年四川省医学会科研课题(S16007)
关键词
结直肠肿瘤
肿瘤转移
贝伐珠单抗
治疗结果
Colorectal neoplasms
Neoplasm metastasis
Bevacizumab
Treatment outcome
